Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2arrest can occur independently of Chk1, Chk2 or MAPKAPK2

(2011) Wen-Hui Zhang et al.   CELL CYCLE

Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

(2010) Yungan Tao et al.   CELL CYCLE

Shift from Apoptotic to Necrotic Cell Death during Human Papillomavirus-induced Transformation of Keratinocytes

(2009) Nataly Kravchenko-Balasha et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

Death through a tragedy: mitotic catastrophe

(2008) H Vakifahmetoglu et al.   CELL DEATH AND DIFFERENTIATION

DNA Damage Repair and Response Proteins as Targets for Cancer Therapy

(2008) Howard Lieberman   CURRENT MEDICINAL CHEMISTRY

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials

(2008) Susan Ashwell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest

(2008) A. A. Levesque et al.   MOLECULAR CANCER THERAPEUTICS